Full description
The objective of this trial is to assess the effectiveness and safety of L-theanine (an amino acid constituent of green tea [Camellia sinensis]) as an adjunctive therapy to treat GAD by conducting a phase II double-blind randomised controlled trial. It is hypothesised that L-theanine will be superior to placebo in reducing anxiety in participants with GAD. The dataset relates to the clinical trial ACTRN12616000759493 L-Theanine in the Adjunctive Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial. This data cannot be shared publicly due to ethics approval conditions. To discuss this data, please contact the NICM Health Research Institute nicm@westernsydney.edu.au.Created: 2025-04-01
Data time period: 12 09 2017 to 30 06 2018
Subjects
L-theanine |
Anxiety |
GAD |
Health |
Health Sciences |
Mental Health |
Nutrition |
Other Health Sciences |
Other Health Sciences Not Elsewhere Classified |
Public Health (Excl. Specific Population Health) |
Randomised controlled trial |
Sleep |
Traditional, Complementary and Integrative Medicine |
Traditional, Complementary and Integrative Medicine Not Elsewhere Classified |
User Contributed Tags
Login to tag this record with meaningful keywords to make it easier to discover
Identifiers
- DOI : 10.26183/Y7W3-5B83
- Local : research-data.westernsydney.edu.au/published/5dd3f5a0a61911efbb9db34536804e8c